赖诺普利联合羟苯磺酸钙治疗糖尿病肾病的临床观察

Efficacy of lisinopril combined with calcium dobesilate on diabetic nephropathy

目的观察赖诺普利联合羟苯磺酸钙治疗糖尿病肾病的临床疗效及安全性。方法选择32例糖尿病肾病患者,随机分为实验组(18例)、对照组(14例)。对照组单用羟苯磺酸钙,实验组在此基础上加用赖诺普利。降糖药根据患者具体情况应用胰岛素皮下注射或口服降糖药治疗,各组疗程均为8周。疗程结束后检测并比较两组患者24 h尿白蛋白排泄率(24 h-UAER)、血肌酐(Scr)及尿素氮(BUN)等指标。结果实验组、对照组总有效率分别为94.5%、71.4%,差异有统计学意义(P<0.05)。治疗后,实验组的24 h-UAER、Scr、BUN较对照组下降明显(P<0.05)。结论赖诺普利联合羟苯磺酸钙治疗糖尿病肾病疗效确切,且无明显不良反应。

Objective To observe the efficacy and safety of lisinopril combined with calcium dobesilate on diabetic nephropathy.Methods 32 patients with diabetic nephropathy were randomly divided into the experiment group（n=18）and control group（n=14）,patients in control group only used calcium dobesilate,experiment group used calcium dobesilate combined with lisinopril.Insulin subcutaneous injection or oral hypoglycemic drug treatment were given according to specific situation of patients,and the treatment period was 8 weeks.The 24 h urinary albumin excretion rate（24 h-UAER）,serum creatinine（Scr）and blood urea nitrogen（BUN）were recorded.Results The total effective rates of experimental group and control group were 94.5% and 71.4% respectively（P〈0.05）.After treatment,The 24 h-UAER,Scr,BUN of experiment group decreased more significantly than those of control group（P〈0.05）.Conclusion The efficacy of lisinopril combined with calcium dobesilate on diabetic nephropathy is accurate without obvious adverse reaction.